DRKS00009691已完成不适用
HepNet patient registry- secondary prevention of hepatic encephalopathy - HE-Register
Deutsche Leberstiftung0 个研究点目标入组 115 人开始时间: 2015年11月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 115
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Patients (> 18 years) with symptomatic hepatic encephalopathy, which required hospitalization in the last 3 months
排除标准
- •hospitalization at baseline.
- •max. 50 patients will be enrolled with MELD> 20 (Should this have a strong negative impact on the recruitment, the number can be increased).
研究者
相似试验
进行中（未招募）
1 期
PROLONGSTEM is a long term follow-up study of all the patients who have received at least one infusion of HepaStemThis study will include all patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HALPC during a previous interventional clinical study conducted by Promethera Biosciences or Promethera Therapeutics including patients suffering from urea cycle disorders (UCD), Crigler-Najjar (CN) and Fibroinflammatory liver diseases.MedDRA version: 20.1Level: LLTClassification code: 10021601Term: Inborn error of metabolism NOS Class: 10010331MedDRA version: 20.0Level: LLTClassification code: 10008954Term: Chronic liver disease and cirrhosis Class: 10019805MedDRA version: 21.1Level: LLTClassification code: 10013373Term: Disorders of urea cycle metabolism Class: 10010331MedDRA version: 20.1Level: LLTClassification code: 10049844Term: Acute liver failure Class: 10019805CTIS2022-500251-22-00Cellaïon SA68
已完成
不适用
A national registration survey of patients with hypertrophic cardiomyopathy in JapaHypertrophic cardiomyopathyJPRN-UMIN000024407Kochi Medical School, Kochi University1,485
招募中
不适用
Clinical registry for patients with primary an recurrent rectal cancerC20Malignant neoplasm of rectumDRKS00015005niversitätsklinikum Freiburg999,999
进行中（未招募）
1 期
PROLONGSTEM is a long term follow-up study of all the patients who have received at least one infusion of HepaStemThis study will include all patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Biosciences including patients suffering from urea cycle disorders (UCD), Crigler-Najjar (CN) and Fibro-inflammatory liver diseasesMedDRA version: 20.1 Level: LLT Classification code 10021601 Term: Inborn error of metabolism NOS System Organ Class: 100000004850MedDRA version: 20.0 Level: LLT Classification code 10008954 Term: Chronic liver disease and cirrhosis System Organ Class: 100000004871MedDRA version: 20.1 Level: LLT Classification code 10049844 Term: Acute liver failure System Organ Class: 100000004871MedDRA version: 20.1 Level: LLT Classification code 10013373 Term: Disorders of urea cycle metabolism System Organ Class: 200000003094EUCTR2017-003989-27-GBPromethera Biosciences22
尚未招募
不适用
Promoting hospital-hospital referral system for hepatitis C virus carriers to hepatologist: multi-center studyHepatitis C virus carriersJPRN-UMIN000029755Kumamoto University2,000